Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Autoimmune encephalitis is brain inflammation caused by the immune system mistakenly reacting against proteins in the brain. The commonest form is called NMDAR-antibody encephalitis (N-methyl-D-aspartate receptor antibody encephalitis), a rare condition which mainly affects children and young people and causes difficulties in memory, thinking and mental health which can have significant long-term impacts on education, employment and quality of life. In this project we will use advanced magnetic resonance imaging (MRI) to measure changes in the structure, function and chemistry of the brains of children and young people who are in early recovery from NMDAR-antibody encephalitis and other forms of immune-mediated encephalitis. We will investigate if MRI measurements in patients differ from those in healthy people, and if they can help predict patient outcome one year later, assessed by tests of memory, thinking, mental health and functioning in daily life.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 8
Maximum Age: 24
Healthy Volunteers: t
View:

⁃ NMDAR-antibody encephalitis group:

• Age 8-24 years at study enrollment.

• Disease onset in the last 12 months before study enrollment.

• Meets consensus diagnostic criteria (Graus et al., 2016) for either probable anti-NMDAR encephalitis OR definite anti-NMDAR encephalitis.

⁃ Antibody-negative autoimmune encephalitis group:

• Age 8-24 years at study enrollment.

• Disease onset in the last 12 months before study enrollment.

• Meets consensus diagnostic criteria (Graus et al., 2016) for either autoantibody-negative but probable autoimmune encephalitis OR definite autoimmune limbic encephalitis.

⁃ Healthy control group:

⁃ 1\. Age 8-24 years at study enrollment.

Locations
Other Locations
United Kingdom
Guy's and St Thomas' NHS Foundation Trust
RECRUITING
London
Contact Information
Primary
Michael R Eyre, MBBS MRes
michael.eyre@kcl.ac.uk
+44 207 1887188
Backup
David W Carmichael, PhD MSci
david.carmichael@kcl.ac.uk
Time Frame
Start Date: 2022-05-19
Estimated Completion Date: 2026-02-28
Participants
Target number of participants: 75
Treatments
NMDAR-antibody encephalitis
Children and young people (ages 8-24 years) with a diagnosis of NMDAR-antibody encephalitis.
Antibody-negative autoimmune encephalitis
Children and young people (ages 8-24 years) with a diagnosis of autoantibody-negative but probable autoimmune encephalitis or definite autoimmune limbic encephalitis.
Healthy control
Healthy children and young people (ages 8-24 years).
Sponsors
Collaborators: Action Medical Research, Guy's and St Thomas' NHS Foundation Trust
Leads: King's College London

This content was sourced from clinicaltrials.gov